Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hoffner

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 3, 2008
The added value of a European Union tuberculosis reference laboratory network--analysis of the national reference laboratory activitiesF A Drobniewski, V Nikolayevskyy, S Hoffner, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 16, 2013
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experienceS Hoffner, K Angeby, E Sturegård, et al.
Annals of Medical and Health Sciences Research|October 27, 2015
Molecular Epidemiology of Mycobacterium Tuberculosis Strains in the North-West and West of IranL Sahebi, K Ansarin, S Hoffner, et al.
Lakartidningen|February 24, 2001
[Tuberculosis a threat again. Multiresistance in the Baltic States and in Russia; Nordic countries initiate cooperation to prevent transmission]A Rutqvist, G Boman, K Ekdahl, et al.
The Journal of Antimicrobial Chemotherapy|May 2, 2013
Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?T Schön, P Juréen, E Chryssanthou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosisS Lockman, A Kruuner, N Binkin, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2017
Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis TreatmentR M Anthony, M Cynamon, S Hoffner, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 28, 2006
Rhodococcus and Mycobacterium Tuberculosis: masquerade or mixed infectionN F Mistry, Y Dholakia, D T B D'Souza, et al.
The Journal of Infectious Diseases|January 1, 1996
Mycobacterium avium complex sputum isolates from patients with respiratory symptoms in Guinea-BissauT Koivula, S Hoffner, N Winqvist, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 15, 2011
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosisT Schön, P Juréen, E Chryssanthou, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 3, 2008
The added value of a European Union tuberculosis reference laboratory network--analysis of the national reference laboratory activitiesF A Drobniewski, V Nikolayevskyy, S Hoffner, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 16, 2013
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experienceS Hoffner, K Angeby, E Sturegård, et al.
Annals of Medical and Health Sciences Research|October 27, 2015
Molecular Epidemiology of Mycobacterium Tuberculosis Strains in the North-West and West of IranL Sahebi, K Ansarin, S Hoffner, et al.
Lakartidningen|February 24, 2001
[Tuberculosis a threat again. Multiresistance in the Baltic States and in Russia; Nordic countries initiate cooperation to prevent transmission]A Rutqvist, G Boman, K Ekdahl, et al.
The Journal of Antimicrobial Chemotherapy|May 2, 2013
Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?T Schön, P Juréen, E Chryssanthou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosisS Lockman, A Kruuner, N Binkin, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2017
Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis TreatmentR M Anthony, M Cynamon, S Hoffner, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 28, 2006
Rhodococcus and Mycobacterium Tuberculosis: masquerade or mixed infectionN F Mistry, Y Dholakia, D T B D'Souza, et al.
The Journal of Infectious Diseases|January 1, 1996
Mycobacterium avium complex sputum isolates from patients with respiratory symptoms in Guinea-BissauT Koivula, S Hoffner, N Winqvist, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 15, 2011
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosisT Schön, P Juréen, E Chryssanthou, et al.
Pageof 4